Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GRM8 | O00222 | 2/20 | 0.36 |
| ▸ | GRM6 | O15303 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9114459 | 1.00 | GABRR1 (0.43) | GABRR1GRM4CYP2C19MEN1KMT2A | |
| SCHEMBL9114483 | 1.00 | GABRR1 (0.43) | GABRR1GRM4CYP2C19MEN1KMT2A | |
| SCHEMBL9114163 | 0.84 | GABRR1 (0.33) | GABRR1GRM4CYP2C19MEN1KMT2A | |
| SCHEMBL23110899 | 0.83 | — | — | |
| SCHEMBL18642165 | 0.83 | — | — | |
| SCHEMBL11629845 | 0.81 | — | — | |
| SCHEMBL638706 | 0.81 | — | — | |
| SCHEMBL29160138 | 0.81 | — | — | |
| SCHEMBL24958749 | 0.81 | — | — | |
| SCHEMBL6791683 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2591040-B1 | ALKYD RESIN | PERSTORP AB (SE) | 2019-08-14 | — | — | EP | claimed |
| EP-2591039-B1 | BRANCHED POLYESTER | PERSTORP AB (SE) | 2018-06-13 | — | — | EP | claimed |
| EP-2591039-A1 | BRANCHED POLYESTER | Perstorp AB (SE) | 2013-05-15 | — | — | EP | claimed |
| EP-2591040-A1 | ALKYD RESIN | Perstorp AB (SE) | 2013-05-15 | — | — | EP | claimed |
| WO-2012005645-A1 | ALKYD RESIN | PERSTORP AB (SE) | 2012-01-12 | — | — | WO | claimed |
| WO-2012005648-A1 | UNSATURATED OLIGIO OR POLYESTER | PERSTORP AB (SE) | 2012-01-12 | — | — | WO | claimed |
| WO-2012005647-A1 | BRANCHED POLYESTER | PERSTORP AB (SE) | 2012-01-12 | — | — | WO | claimed |
| CN-115521999-A | Preparation method and application of tanning mending paste based on tanning solid waste | 兴业皮革科技股份有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| WO-2016123146-A1 | BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123146-A1 | BRIDGED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORP. (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-3050888-A1 | Compounds for the treatment of bacterial infections | Merck Sharp & Dohme Corp. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-0856025-B1 | CHOLESTERIC PHASE-FORMING POLYMERS AND THEIR USE | CELANESE VENTURES GMBH (DE) | 2003-01-15 | — | — | EP | disclosed |
| US-6107447-A | LIQUID CRYSTALLINE POLYMERS | HOECHST RESEARCH TECHNOLOGY DEUTCHLAND GMBH & CO. KG (DE) | 2000-08-22 | — | — | US | disclosed |
| EP-0856025-A1 | CHOLESTERIC PHASE-FORMING POLYMERS, PROCESS FOR THEIR PREPARATION AND THEIR USE | Hoechst Research & Technology Deutschland GmbH & Co. KG (DE) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997014739-A1 | CHOLESTERIC PHASE-FORMING POLYMERS, PROCESS FOR THEIR PREPARATION AND THEIR USE | HOECHST RESEARCH & TECHNOLOGY (DE) | 1997-04-24 | — | — | WO | disclosed |
| WO-1995007022-A1 | FUNGICIDES | ZENECA LIMITED (GB) | 1995-03-16 | — | — | WO | disclosed |
| US-5276169-A | Antimycotic carbonyl- and amino-substituted tetrahydrofurans | BAYER AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | disclosed |
| EP-0538688-A1 | Substituted tetrahydrofurans, methods for their preparation, and their use as pharmaceutical compositions | BAYER AG (DE) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, HTR1D, RXFP1 | GABRR1 606/4885GRM4 1582/4885CYP2C19 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.